Capstone Investment Advisors
ALNY icon

Capstone Investment Advisors’s Alnylam Pharmaceuticals ALNY Stock Holding History

Capstone Investment Advisors’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-5,300
Closed -$2.11M – 1567
2025
Q4 		$2.11M Buy
+5,300
New +$2.35M ﹤0.01% 605
2020
Q3 		– Sell
-40,000
Closed -$5.92M – 1385
2020
Q2 		$5.92M Hold
40,000
– – 0.04% 378
2020
Q1 		$4.35M Buy
+40,000
New +$4.62M 0.07% 308

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capstone Investment Advisors's ALNY Position: Q1 2026 in Review

Capstone Investment Advisors reduced its Alnylam Pharmaceuticals (ALNY) stake by 92% in Q1 2026, selling an estimated $2.78M and leaving 753 shares worth $249K. The position accounts for ﹤0.01% of the portfolio, ranked #1439.

Capstone Investment Advisors first reported a position in ALNY in Q1 2016 and has held it in 6 quarters since. The position peaked at $3.55M in Q4 2025. 787 funds tracked by Wall St. Rank hold ALNY as of Q1 2026.

  • Capstone Investment Advisors held 753 shares of Alnylam Pharmaceuticals worth $249K as of Q1 2026.
  • Capstone Investment Advisors sold 8,165 Alnylam Pharmaceuticals shares in Q1 2026, an estimated $2.78M.
  • Alnylam Pharmaceuticals made up ﹤0.01% of Capstone Investment Advisors's portfolio in Q1 2026, its #1439 holding.
  • Capstone Investment Advisors first reported a position in Alnylam Pharmaceuticals in Q1 2016 and has held it in 6 quarters since.
  • Capstone Investment Advisors's Alnylam Pharmaceuticals position peaked at $3.55M in Q4 2025.
  • 787 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q1 2026.

Based on Capstone Investment Advisors's 13F filing for Q1 2026, filed 15 May 2026.